This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Cefoxitin injection

Updated 2 Feb 2023 | Cephalosporins


Powder for solution for injection containing cefoxitin.

Drugs List

  • cefoxitin 1g powder for solution for injection vial
  • cefoxitin 2g powder for solution for injection vial
  • RENOXITIN 1g powder for solution for injection vial
  • RENOXITIN 2g powder for solution for injection vial
  • Therapeutic Indications


    Complicated urinary tract infections

    Cefoxitin is indicated for the treatment of complicated urinary tract infections and pyelonephritis, in infections known to be caused by pathogens susceptible to cefoxitin and for which other, more commonly prescribed antibacterial agents are not appropriate.



    2g every 4 to 6 hours, maximum dose of 12g per day.


    Children aged 11 to 18 years old
    2g every 4 to 6 hours, maximum dose of 12g per day.

    Patients with Renal Impairment

    Creatinine clearance 30 to 50ml/minute: initial dose of 2g, followed by maintenance dose of 2g every 8 to 12 hours.
    Creatinine clearance 10 to 29ml/minute: initial dose of 2g, followed by maintenance dose of 2g every 12 to 24 hours.

    In patients receiving haemodialysis, the initial dose of 2g should be given after haemodialysis.


    Children under 11 years

    Precautions and Warnings

    Renal impairment

    Haemodialysis patients: administer drug after dialysis
    Advise patient ability to drive or operate machinery may be impaired
    Before initiating therapy enquire about previous hypersensitivity reactions
    Treatment to be initiated and supervised by a specialist
    Monitor urine of diabetic patients for ketones
    Consider pseudomembranous colitis if patient presents with diarrhoea
    Prolonged use may result in superinfection with non-susceptible organisms
    May affect results of some laboratory tests
    Discontinue at once if pseudomembranous colitis occurs
    Discontinue if hypersensitivity reactions occur

    Antibiotic-associated colitis have been reported with anti-bacterial agents and may occur with cefoxitin use. Consider colitis in patients present with diarrhoea during or subsequent to cefoxitin administration. If such symptoms occur, consider discontinuation of treatment and consider use of other supportive measures. Medicinal products that inhibit peristalsis should not be used.

    The use of beta-lactam antibiotics increases the risk of encephalopathy. Cefoxitin may have major influence on the ability to drive and use machines due to the increased risk of the occurrence of encephalopathy.

    Pregnancy and Lactation


    Use cefoxitin with caution during pregnancy.

    The manufacturer recommends that cefoxitin should only be used during pregnancy if clinically needed.

    At the time of writing there is limited published information regarding the use of cefoxitin during pregnancy. Potential risks are unknown. Animal studies have not shown evidence of teratogenic effects.


    Cefoxitin is contraindication during breastfeeding.

    The manufacturer recommends that cefoxitin should be discontinued during breastfeeding to prevent hypersensitivity reactions in the infant.

    Cefoxitin is known to be excreted in milk.

    Side Effects

    Altered consciousness
    Anaphylactic reaction
    Bone marrow failure
    Exacerbation of myasthenia gravis
    Increase in alkaline phosphatase
    Increase in blood urea nitrogen
    Increase in lactate dehydrogenase
    Increase in serum transaminases
    Interstitial nephritis
    Local reaction at injection site
    Movement disturbances
    Pseudomembranous colitis
    Renal impairment
    Serum creatinine increased
    Thrombophlebitis (localised)
    Toxic epidermal necrolysis

    Effects on Laboratory Tests

    Coombs tests:
    False-positive coombs test results have been observed in treatment with cephalosporins, this may occur with cefoxitin treatment.

    Glucose in the urine:
    A false-positive reaction may occur with reducing substances but not with specific glucose oxidase methods

    Serum creatinine levels:
    Levels should not be taken within two hours of drug administration.
    Using the Jaffe method, falsely high serum creatinine levels may occur if cefoxitin serum concentrations are greater than 100 micrograms / ml

    Porter-Silber method of measuring 17-hydroxy-corticosteroids may give slightly falsely increased results if there is high concentration of cefoxitin in the urine.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2019

    Reference Sources

    Summary of Product Characteristics: Renoxitin 2g Powder for solution for injection or infusion. Revised: April 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.